Germline BRCA1/2 mutations are identified in up to 15% of serous ovarian cancer, while an additional 5–7% of ovarian cancers harbor somatic BRCA1/2 mutations [3]. This evidence concerns the gene BRCA1 and ovarian carcinoma.